AR and prostate cancer: Interestingly, the ongoing clinical studies involving the administration of supraphysiological androgen levels, inducing AR-mediated induction of DNA double-strand breaks, cell cyle arrest, and cellular senescence showed preferential responsiveness of prostate cancer patients with mutations in genes mediating homology-directed DNA repair [723].